NasdaqGS:COLLPharmaceuticals
How Collegium's Quarterly Beat but Softer Outlook Could Reframe Collegium Pharmaceutical (COLL) Investors
In its latest quarterly update, Collegium Pharmaceutical reported US$193.5 million in revenue, topping analyst estimates and delivering earnings per share ahead of expectations, but issued full-year revenue guidance that fell short of consensus forecasts.
This contrast between strong recent execution and more cautious guidance has sharpened investor focus on how management views the company’s medium-term growth prospects and product momentum.
We’ll now examine how Collegium’s revenue beat...